tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Tvardi Therapeutics Faces Legal and Financial Risks from Exclusive Forum Provision
PremiumCompany AnnouncementsTvardi Therapeutics Faces Legal and Financial Risks from Exclusive Forum Provision
2M ago
Tvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last year
Premium
The Fly
Tvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last year
2M ago
Tvardi Therapeutics expects cash to fund operations into Q4 2026
Premium
The Fly
Tvardi Therapeutics expects cash to fund operations into Q4 2026
2M ago
Tvardi Therapeutics Updates Corporate Presentation on Therapies
PremiumCompany AnnouncementsTvardi Therapeutics Updates Corporate Presentation on Therapies
4M ago
Tvardi Therapeutics files to sell 2.08M shares of common stock for holders
Premium
The Fly
Tvardi Therapeutics files to sell 2.08M shares of common stock for holders
4M ago
Buy Rating for Tvardi Therapeutics Driven by Promising Phase 2 Trial Results and Growth Potential
Premium
Ratings
Buy Rating for Tvardi Therapeutics Driven by Promising Phase 2 Trial Results and Growth Potential
5M ago
Promising Developments and Strong Financial Position Drive Buy Rating for Tvardi Therapeutics
PremiumRatingsPromising Developments and Strong Financial Position Drive Buy Rating for Tvardi Therapeutics
5M ago
Tvardi Therapeutics initiated with a Buy at BTIG
Premium
The Fly
Tvardi Therapeutics initiated with a Buy at BTIG
5M ago
Tvardi Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Tvardi Therapeutics Reports Q1 2025 Financial Results
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100